Adoption of Global Quality Standards is required for Indian Pharma: OPPI

OPPI stands for the Organisation of Pharmaceutical Producers of India and it represents the research-based pharmaceutical companies in India. It completely engages with the government and other stakeholders to find the best sustainable healthcare solutions.

According to OPPI, Indian pharma required to adopt global quality standards to gain the growth of the sector and bring all stakeholders like regulators, industry, and governments to work jointly towards it.

WHO (World Health Organisation) has set some quality standards like GMP(Good Manufacturing Practices) and Indian pharma should need to maintain uniform baseline with them. Kanchana, OPPI director general said that the medicine making process should follow the global standards and need to implement from initial manufacturing stage to the delivery chain.

To address the quality issues in the pharmaceutical industry, all the government officials, industry representatives, industry associations and patient groups met in the Summit. All were discussed about the gamut of issues covering quality, ranging from labeling to packaging and storage at the summit.

Uttar Pradesh Department of Food Safety and Drug Administration study reports that around 38% of medicines are not effective as they are the outcome of low-quality standards. India has a number of pharmaceutical manufacturing industries but no quality standards maintained across the board.

To raise manufacturing quality standards, the government need to work with industry associations and other stakeholders including patient groups that represent the public and have to work together. That step will keep India globally competitive and Indian drugs sought after in global markets. Challenges like regulatory issues need to be addressed on the urgent basis for the growth of the Indian pharmaceutical industry.

Kanchana also commented on Government policies that policies should be more predictable and should remain for 3-5 years and Pharma Industry is in the need to have progressive policy changes.

OPPI just want to convey the importance of quality in delivering responsible and safe patient care as the quality of the medicine also plays an important role in cure process.

Related Posts

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

Mumbai: A promoter entity of Ajanta Pharma Ltd. on Tuesday offloaded a nearly 3% stake in the company through open market transactions, even as domestic institutional investors stepped in to absorb a large…

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

Pune: In a major crackdown against illegal pharmaceutical activities that compromise public health, the Food and Drug Administration (FDA) has seized a stock of medicines worth above Rs24.81 lakh from…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

Pvt nursing home sealed in Chatra after woman, unborn baby die

Pvt nursing home sealed in Chatra after woman, unborn baby die

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy